News
Novartis drug Afinitor® approved by FDA as first medication for children and adults with a benign brain tumor associated with tuberous sclerosis PharmPro
View ArticleA Double Dose of Trouble for Big Pharma?
A Double Dose of Trouble for Big Pharma? Motley Fool
View ArticleNovartis’s Afinitor Wins FDA Approval for Jobs’s Cancer Type
Novartis’s Afinitor Wins FDA Approval for Jobs’s Cancer Type Bloomberg
View ArticleNovartis Adds New Drug Approvals In May
Novartis Adds New Drug Approvals In May Investor's Business Daily
View ArticleNovartis to File Drug for Breast Cancer
Novartis to File Drug for Breast Cancer WSJ Online
View ArticleNovartis gets European approval for Afinitor
Novartis gets European approval for Afinitor Marketwatch
View ArticleAfinitor data could be 'game-changer' in breast cancer
Afinitor data could be 'game-changer' in breast cancer Fierce Pharma
View ArticleNovartis Drug Afinitor May Be A Blockbuster Breast Cancer Treatment
Novartis Drug Afinitor May Be A Blockbuster Breast Cancer Treatment Seeking Alpha
View ArticleBig promise is seen in 2 new breast cancer drugs
Big promise is seen in 2 new breast cancer drugs Yahoo/AP
View ArticleNovartis' Afinitor recommended by CHMP for EU approval
Novartis' Afinitor recommended by CHMP for EU approval Yahoo/Fly on the Wall
View ArticleUPDATE 2-US FDA approves Novartis drug Afinitor for breast cancer
UPDATE 2-US FDA approves Novartis drug Afinitor for breast cancer Reuters
View ArticleBreast Cancer Halted By Novartis Drug From Easter Island
Breast Cancer Halted By Novartis Drug From Easter Island Bloomberg
View ArticleNovartis drug Afinitor gets EU nod for breast cancer
Novartis drug Afinitor gets EU nod for breast cancer Reuters
View ArticleNovartis says Afinitor reduces tumors in rare genetic disease
Novartis says Afinitor reduces tumors in rare genetic disease Reuters
View ArticleU.K. Regulators Sour on Novartis Breast Cancer Drug Afinitor
U.K. Regulators Sour on Novartis Breast Cancer Drug Afinitor Motley Fool
View ArticleTackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players
Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players Motley Fool
View Article
